妇科肿瘤扩大野放疗肾毒性剂量学预测因素
研究纳入98例接受扩大野放疗(EFRT)或全盆腔放疗(WPRT)并同步顺铂化疗的宫颈或子宫内膜癌患者,分析肾脏剂量体积直方图与治疗前后eGFR比值的关系。结果显示EFRT患者KV20Gy与eGFR下降强相关,KV20Gy<10%者肾功能保留显著更优(P=0.002)。
要点
- EFRT患者肾脏V20Gy与治疗前后eGFR比值强相关(r=-0.80)。
- EF-IMRT患者肾脏V20Gy<10%者肾功能显著优于>10%者(P=0.002)。
- WPRT同步顺铂后12个月内eGFR基本不变,与EFRT不同。
核心结论
- EF-IMRT期间施加严格的肾脏剂量约束可能减少肾毒性。
研究设计与样本
- 单中心回顾性分析,2012年7月至2020年4月纳入98例宫颈或子宫内膜癌患者,其中34例接受EFRT(含EF-IMRT),64例接受WPRT同步顺铂。
- 排除6个月内复发者后,对31例EFRT患者分析肾脏剂量体积直方图(V12Gy、V16Gy、V20Gy、V24Gy)与治疗前后eGFR比值。
主要发现
- WPRT同步顺铂后12个月内eGFR基本不变,而EFRT后eGFR下降。
- EFRT患者肾脏V20Gy与治疗前后eGFR比值强相关,相关系数-0.80(全部患者)和-0.74(EF-IMRT患者)。
- EF-IMRT患者肾脏V20Gy与eGFR下降呈负相关趋势。
- Mann-Whitney U检验显示KV20Gy<10%患者肾功能保留显著优于KV20Gy>10%者(P=0.002)。
关键数值与推荐
- EF-IMRT患者肾脏KV20Gy<10%与>10%组间肾功能保留差异有统计学意义(P=0.002)。
临床怎么用
- EF-IMRT计划设计时应关注肾脏V20Gy,尽量使KV20Gy<10%以保留肾功能。
局限性
- 回顾性单中心研究,EFRT分析样本量较小(31例),需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We sought dosimetric predictors of a decreasing estimated glomerular filtration rate (eGFR) in gynecological oncology patients receiving extended-field radiation therapy (EFRT). MATERIALS AND METHODS: Between July 2012 and April 2020, 98 consecutive cervical or endometrial cancer patients underwent EFRT or whole-pelvis radiation therapy (WPRT) with concurrent cisplatin chemotherapy in our institution. To explore the effect of concurrent cisplatin chemotherapy on renal function, the renal function of the WPRT patients was examined. Of the 98 patients, 34 cervical or endometrial cancer patients underwent EFRT including extended-field intensity-modulated radiation therapy (EF-IMRT) and 64 cervical cancer patients underwent WPRT with cisplatin. Of the 34 EFRT patients, 32 underwent concurrent cisplatin chemotherapy. Excluding patients exhibiting recurrences within 6 months, 31 EFRT patients were analyzed in terms of the dose-volume kidney histograms (the percentages of kidney volumes receiving 12, 16, 20, and 24 Gy) and the post- to pre-treatment eGFR ratios. We calculated Pearson correlation coefficients between the renal dose volume and the percentage eGFR reductions of the 31 EFRT patients, and those treated via EF-IMRT. Renal dose constraint significance was evaluated using the Mann-Whitney U test. RESULTS: The eGFR value after WPRT with cisplatin remained largely unchanged for 12 months, unlike that after EFRT. In EFRT patients, a strong correlation was evident between the KV20Gy dose and the post- to pre-treatment eGFR ratio (correlation coefficients - 0.80 for all patients and - 0.74 for EF-IMRT patients). In EF-IMRT patients, the kidney volume receiving 20 Gy tended to correlate negatively with the eGFR reduction. The Mann-Whitney U test showed that patients with KV20Gy values < 10% retained significantly better renal function than did patients with KV20Gy values > 10% (P = 0.002). CONCLUSIONS: Imposition of a severe kidney dose constraint during EF-IMRT may reduce nephrotic toxicity. Future prospective investigations of kidney-sparing EF-IMRT are required.
引用
- Kunogi H, Yamaguchi N, Terao Y, et al. Dosimetric predictors of nephrotoxicity in patients receiving extended-field radiation therapy for gynecologic cancer. Radiat Oncol. 2021. PMID: 33541379. doi:10.1186/s13014-021-01755-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。